Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Hemodialysis

New Methods and Future Technology

Editor(s): Ronco C. (Vicenza) 
Rosner M.H. (Charlottesville, Va.) 
Cover

Evolution of Dialysis Membranes

Recent Trials on Hemodiafiltration

Locatelli F. · Manzoni C · Del Vecchio L. · Cavalli A. · Pontoriero G.

Author affiliations

Department of Nephrology, Dialysis and Renal Transplant, Alessandro Manzoni Hospital, Lecco, Italy

Related Articles for ""

Ronco C, Rosner MH (eds): Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011, vol 171, pp 92–100

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Evolution of Dialysis Membranes

Published online: May 23, 2011
Cover Date: 2011

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 2

ISBN: 978-3-8055-9771-5 (Print)
eISBN: 978-3-8055-9772-2 (Online)

Abstract

The theoretical advantages of high-flux hemodialysis (HD) in treating patients with chronic kidney disease (CKD) stage 5 are related to the higher toxin removal (especially ‘middle molecules’), including sodium and water, and to the better biocompatibility of the treatment, including membrane and water quality. Several observational studies have shown that high-flux HD has positive effects on the survival and morbidity of uremic patients when compared with low-flux HD. The primary analysis of the prospective randomized HEMO (Hemodialysis Outcomes) study showed that high-flux HD was associated with an 8% nonsignificant reduction of mortality in comparison with low-flux HD. However, a secondary analysis pointed to an advantage for high-flux HD in subgroups of patients. More recently, the MPO (Membrane Permeability Outcome) study found that survival could be significantly improved by using high-flux HD compared with low-flux HD in high-risk patients as identified by serum albumin ≤4 g/dl and, in a post hoc analysis, in diabetic patients as a whole. On-line hemodiafiltration (HDF) is considered the most efficient technique of using high-flux membranes. Clearance of small solutes like urea are higher than in hemofiltration, and clearance of middle solutes like β2- microglobulin are higher than in high-flux HD. Since there is only a very limited number of randomized prospective trials comparing HDF and high-flux HD, no conclusive data are available about the effect of increased convection of on-line HDF on survival and morbidity of CKD patients. The suggested advantages of HDF must be confirmed by a large randomized controlled study.

© 2011 S. Karger AG, Basel


References

  1. Von Albertini B, Miller JH, Gardner PW, Shinaberger JH: High-flux hemodiafiltration: under six hours/ week treatment. Trans Am Soc Artif Internal Organs 1984;30:227-231
  2. Del Vecchio L, Locatelli F, Carini M: What we know about oxidative stress in patients with chronic kidney disease on dialysis - clinical effects, potential treatment, and prevention. Semin Dial 2011;24:56-64
  3. Leypoldt JK, Cheung AK, Carroll CE, Stannard C, Pereira BJG, Agodoa LY, Port FK: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999;33:349-355
  4. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019
  5. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263
  6. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R: Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:645-654
  7. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-1006
  8. The DOPPS Report. 2004;http://www.dopps.org/pdf/dopps_report_2004.pdf. Accessed June 30, 2007
  9. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277
  10. Cheung AK, Greene T: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:462-464
  11. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006;17:546-555
  12. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007;22:ii5-ii21
  13. Tattersal J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van Biesen W: European Renal Best Practice Advisory Board: High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol Dial Transplant 2010;25:1230-1232
  14. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218
  15. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187
  16. Zehnder C, Gutzwiller JP, Renggli K: Hemodiafiltration: a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152-159
  17. Penne EL, van der Weerd NC, van der Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, Bots ML, Blankestijn PJ, ter Wee PM: CONTRAST Investigators: Short-term effects of on-line hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 2010;55:77-87
  18. Maduell F, del Pozo C, Garcia H, Sanchez L, Hdez-Jaras J, Albero MD, Calvo C, Torregrosa I, Navarro V: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999;14:1202-1207
  19. Schiffl H, Lang SM, Bergner A: Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999;83:278-279
  20. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003;42:524-531
  21. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002;17:1045-1049
  22. Pizzarelli F, Cerrai T, Dattolo P, Tetta C, Maggiore Q: Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. Nephrol Dial Transplant 1998;13:363-369
  23. Lin CL, Huang CC, Chang CT, Wu MS, Hung CC, Chien CC, Yang CW: Clinical improvement by increased frequency of on-line hemodiafiltration. Renal Failure 2001;23:193-206
  24. Maggiore Q, Pizzarelli F, Sisca S, Zoccali C, Parlongo S, Nicolò F, Creazzo G: Blood temperature and vascular stability during hemodialysis and hemofiltration. Trans Am Soc Artif Intern Organs 1982;28:523-537
  25. Donauer J, Schweiger C, Rumberger B, Krumme B, Bohler J: Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003;18:1616-1622
  26. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999;155:286-293
  27. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101
  28. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G: HEMO Study Group: Association between serum beta2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:69-77
  29. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G: Italian Cooperative Dialysis Study Group: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;50:1293-1302
  30. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001;19:301-307
  31. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000;11:2344-2350
  32. Locatelli F, Di Filippo S, Manzoni C: Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant 2000;15:(Suppl 2)37-44
  33. Wizemann V, Lotz C, Techert F, Uthoff S: On-line haemodiafiltration versus low-flux haemodialysis: a prospective randomized study. Nephrol Dial Transplant 2000;15:(Suppl 1)43-48
  34. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093
  35. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R: RISCAVID Study Group: Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008;23:2337-2343
  36. Santoro A, Mancini E, Bolzani R, Boggi R, Cagnoli l, Francioso A, Fusaroli M, Piazza V, Rapanà R, Strippoli GF: The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 2008;52:507-518
  37. Bolasco P, Altieri P, Andrulli S, Basile C, Di Filippo S, Feriani M, Pedrini L, Santoro A, Zoccali C, Sau G, Locatelli F: Convection versus diffusion in dialysis: an Italian prospective multi-centre study. Nephrol Dial Transplant 2003;18:(Suppl 7)vii50-vii54
  38. Locatelli F, Altieri P, Andrulli S, Bolasco P, Sau G, Pedrini LA, Basile C, David S, Feriani M, Montagna G, Di Iorio BR, Memoli B, Cravero R, Battaglia G, Zoccali C: Hemofiltration and hemodiafiltration reduce intra-dialytic hypotension in ESRD. J Am Soc Nephrol 2010;21:1798-1807
  39. Penne EL, Blankestijn PJ, Bots ML, Van den Dorpel MA, Grooteman MP, Nubé MJ, Ter Wee PM: CONTRAST Group: Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 2005;18:47-51
  40. Pedrini L, De Cristofaro V, Comelli M, Casino FG, Prencipe M, Baroni A, Campolo G, Manzoni C, Colì L, Ruggiero P, Acquistapace I, Auriemma L: Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multi-centre prospective randomized study. Nephrol Dial Transplant 2011;E-pub ahead of print

Article / Publication Details

First-Page Preview
Abstract of Evolution of Dialysis Membranes

Published online: May 23, 2011
Cover Date: 2011

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 2

ISBN: 978-3-8055-9771-5 (Print)
eISBN: 978-3-8055-9772-2 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.